Erratum: Differential effects on T-cell function following exposure to serum from schizophrenia smokers (Molecular Psychiatry (2008) DOI: 10.1038/mp.2008.120);Differential effects on T-cell function following exposure to serum from schizophrenia smokers

Molecular Psychiatry

Volumn 15, Issue 4, 2010, Pages 364-371

  Herberth, M ^a   Krzyszton, D N ^a   Koethe, D ^b   Craddock, M R ^a   Bulger, E ^a   Schwarz, E ^a   Guest, P ^a   Leweke, F M ^b   Bahn, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Activation marker; Cotinine; Cytokine; Schizophrenia; Smoking; T cell signaling

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; COTININE; DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE SURFACE MARKER; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCHIZOPHRENIA; SMOKING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 77950021894     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.137     Document Type: Erratum

References (45)

1. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002; 56: 47-54.
2. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998; 33: 113-118.
3. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005; 14: 106-123.
4. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155: 1490-1501.
5. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23: 247-254.
6. Kumari V, Postma P. Nicotine use in schizophrenia: The self medication hypotheses. Neurosci Biobehav Rev 2005; 29: 1021.
7. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 2004; 55: 850-858.
8. Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA et al. Nicotine improves delayed recognition in schizophrenia patients. Psychopharmacology (Berl) 2004; 174: 334-340.
9. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115.
10. Brown S, Barraclough B, Inskip H. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
11. Holt PG, Keast D. Environmentally induced changes in immuno-logical function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. Bacteriol Rev 1977; 41: 205-216.
12. Johnson JD, Houchens DP, Kluwe WM, Craig DK, Fisher GL. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: a review. Crit Rev Toxicol 1990; 20: 369-395.
13. Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. J Immunol 1996; 156: 2384-2390.
14. Geng Y, Savage SM, Johnson LJ, Seagrave J, Sopori ML. Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes. Toxicol Appl Pharmacol 1995; 135: 268-278.
15. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H et al. Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. J Pharmacol Exp Ther 2004; 311: 758-769.
16. Kalra R, Singh SP, Kracko D, Matta SG, Sharp BM, Sopori ML. Chronic self-administration of nicotine in rats impairs T cell responsiveness. J Pharmacol Exp Ther 2002; 302: 935-939.
17. Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Moller HJ et al. Decreased T cellular immune response in schizophrenia patients. J Psychiatr Res 2007; 41: 3-7.
18. Craddock RM, Lockstone HE, Rider DA, Wayland MT, Harris LJ, McKenna PJ et al. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS ONE 2007; 2: e692.
19. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
20. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76: 135-157.
21. Haley NJ, Sepkovic DW, Hoffmann D. Elimination of cotinine from body fluids: disposition in smokers and nonsmokers. Am J Public Health 1989; 79: 1046-1048.
22. Benowitz NL, Jacob III P. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 1993; 53: 316-323.
23. Valitutti S, Muller S, Salio M, Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med 1997; 185: 1859-1864.
24. Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 1991; 147: 3165-3169.
25. Huhn J, Ehrlich S, Fleischer B, von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett 2000; 72: 127-132.
26. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
27. Hemar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol 1995; 129: 55-64.
28. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-1194.
29. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenia patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156: 1751-1757.
30. Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry 2001; 42: 393-402.
31. Esterberg ML, Jones EM, Compton MT, Walker EF. Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls. Schizophr Res 2007; 97: 6-13.
32. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-1047.
33. McCue JM, Link KL, Eaton SS, Freed BM. Exposure to cigarette tar inhibits ribonucleotide reductase and blocks lymphocyte proliferation. J Immunol 2000; 165: 6771-6775.
34. Glader P, Moller S, Lilja J, Wieslander E, Lofdahl C-G, von Wachenfeldt K. Cigarette smoke extract modulates respiratory defence mechanisms through effects on T-cells and airway epithelial cells. Respir Med 2006; 100: 818.
35. Rehani K, Scott DA, Renaud D, Hamza H, Williams LR, Wang H et al. Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim Biophys Acta 2008; 1783: 375-382.
36. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S et al. Nicotinic acetylcholine receptor [alpha]7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384.
37. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neu-roimmunomodulation. Mol Med 2003; 9: 125-134.
38. Perl O, Ilani T, Strous RD, Lapidus R, Fuchs S. The α7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J 2003 03-0104fje.
39. James FP, Dixon JLL, Favero JJ. Activation of human T lymphocytes by crosslinking of anti-CD3 monoclonal antibodies. J Leukoc Biol 1989; 46: 214-220.
40. Nel AE. T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immunol 2002; 109: 758-770.
41. Matloubi H, Vodjgani M, Nasehi AA, Niknam MH, Kazemnejad A, Salehi E et al. Decreased T cell response to mitogen and increased anti-cytoplasmic antibody in drug-free schizophrenia patients. Iran J Immunol 2007; 4: 32-37.
42. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. Tcell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci USA 2004; 101: 8180-8185.
43. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5: 49.
44. Huang JTJ, Leweke FM, Oxley D, Wang L, Harris N, Koethe D et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006; 3: e428.
45. Huang JTJ, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 2007; e-pub ahead of print 16 October 2007